RxCapital

RxCapital deploys capital at the earliest institutional stages — seed and Series A. The firm's typical check size ranges from £250,000 to £3 million, positioning it as a nucleus investor that can anchor a round before later-stage venture funds enter. Its stage focus aligns with the high-risk, pre-revenue profile of drug-development startups and early health-tech platforms.

RxCapital does not invest outside healthcare. The firm's mandate excludes clean energy, fintech, enterprise software, consumer internet, and industrials — a deliberate narrowing that differentiates it from generalist venture shops. This sector discipline means the team evaluates fewer deals annually but with deeper clinical and scientific due diligence for each.

The firm leans on the Cambridge life-science ecosystem — university spinouts, research-hospital collaborations, and technology-transfer offices — as primary sourcing channels. Its geographic concentration gives it early visibility into companies emerging from University of Cambridge labs and affiliated healthcare clusters before those startups are widely shopped to pan-European funds.

RxCapital operates as a venture-oriented private equity firm, not a buyout shop. It focuses on minority-equity investments in early-stage companies, earning returns through long-duration equity appreciation rather than financial engineering or leveraged dividends. The GP structure is the standard tiered partnership model for closed-end funds.